SeaSpine Holdings Corporation (SPNE)
(Delayed Data from NSDQ)
$15.36 USD
+0.73 (4.99%)
Updated May 3, 2019 04:00 PM ET
After-Market: $15.40 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.36 USD
+0.73 (4.99%)
Updated May 3, 2019 04:00 PM ET
After-Market: $15.40 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
PerkinElmer (PKI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
PerkinElmer's (PKI) Q4 earnings benefits from higher revenues and growth in DAS and Diagnostics segments. However, forex remains a woe.
Hill-Rom's (HRC) Q1 Earnings Top Estimates, Revenues In Line
by Zacks Equity Research
Sales in Hill-Rom's (HRC) Surgical Solutions suffer a massive setback, thanks to the divestiture of surgical consumables.
Moving Average Crossover Alert: SeaSpine
by Zacks Equity Research
SeaSpine Holdings Corporation (SPNE) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
SeaSpine Holdings (SPNE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
SeaSpine (SPNE) delivered earnings and revenue surprises of -27.50% and 3.66%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
SeaSpine Holdings (SPNE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
SeaSpine (SPNE) delivered earnings and revenue surprises of 7.32% and 0.92%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
SeaSpine Holdings (SPNE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
SeaSpine (SPNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will SeaSpine Holdings (SPNE) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
SeaSpine (SPNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SeaSpine Holdings (SPNE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
SeaSpine (SPNE) delivered earnings and revenue surprises of -14.29% and 1.20%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will SeaSpine Holdings (SPNE) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
SeaSpine (SPNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SeaSpine Holdings (SPNE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
SeaSpine (SPNE) delivered earnings and revenue surprises of -22.64% and 0.76%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
SeaSpine Holdings (SPNE) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
SeaSpine (SPNE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: BioLife Solutions, SeaSpine Holdings, Apollo Endosurgery and CareDx
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BioLife Solutions, SeaSpine Holdings, Apollo Endosurgery and CareDx
4 Top-Ranked Growth Stocks in MedTech Under $20
by Zacks Equity Research
In the wake of the turbulent political scenario and banking on favorable metrics, these four MedTech stocks stand out as the most suitable picks.
4 Top Growth Picks to Avoid Tax Tangle in MedTech
by Zacks Equity Research
Despite the ongoing tax bill-related disputes in the MedTech industry, these stocks with high growth potential can be great bets for investors.
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, SeaSpine Holdings and EnteroMedics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, SeaSpine Holdings and EnteroMedics
4 Momentum Stocks That May Survive the Health Policy Mess
by Zacks Equity Research
In view of the current political scenario and banking on favorable metrics, these four MedTech stocks stand out as the most suitable momentum picks.